Advances in Treatment of Diffuse Midline Gliomas
Related Experiment Video
Updated: Jul 11, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Chantel Cacciotti1, Karen D Wright2
1Children's Hospital London Health Sciences/Western University, London, ON, Canada. Chantel.Cacciotti@lhsc.on.ca.
Purpose Of Review:
Diffuse midline gliomas (DMGs) generally carry a poor prognosis, occur during childhood, and involve midline structures of the central nervous system, including the thalamus, pons, and spinal cord.
Recent Findings:
To date, irradiation has been shown to be the only beneficial treatment for DMG. Various genetic modifications have been shown to play a role in the pathogenesis of this disease. Current treatment strategies span targeting epigenetic dysregulation, cell cycle, specific genetic alterations, and the immune microenvironment. Herein, we review the complex features of this disease as it relates to current and past therapeutic approaches.
Insights
Diffuse midline gliomas (DMGs) are aggressive childhood brain tumors. While radiation offers some benefit, new therapies targeting genetic and immune factors are under investigation.
Area of Science:
- Pediatric oncology
- Neuro-oncology
- Cancer genetics
Background:
- Diffuse midline gliomas (DMGs) are aggressive pediatric brain tumors.
- These tumors involve critical midline structures of the central nervous system.
- DMGs are associated with a poor prognosis.
Purpose of the Study:
- To review the complex features of diffuse midline gliomas.
- To discuss current and past therapeutic approaches for DMGs.
- To highlight the role of genetic modifications in DMG pathogenesis.
Main Methods:
- Literature review of DMG studies.
- Analysis of current treatment strategies.
- Examination of genetic alterations and immune microenvironment.
Main Results:
- Irradiation is the only established beneficial treatment for DMG.
- Genetic modifications are key in DMG development.
- Targeting epigenetic dysregulation, cell cycle, genetics, and the immune microenvironment are current strategies.
Conclusions:
- DMG treatment remains challenging due to poor prognosis.
- Further research into targeted therapies is crucial.
- Understanding genetic and immune factors may improve outcomes.
